What is Provexis plc's (PXS.L) StockRank?

MoatMap's StockRank for Provexis plc (PXS.L) is 44/100, with a Hold signal. This is a composite score combining Quality (40), Value (24), and Momentum (74) factor ranks across MoatMap's 20,000+ stock universe.

Does Provexis plc have an economic moat?

Provexis plc (PXS.L) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Provexis plc a buy, hold, or sell?

MoatMap's current signal for Provexis plc (PXS.L) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Provexis plc in?

Provexis plc (PXS.L) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PXS.L

HOLD

Provexis plc · Healthcare · United Kingdom · $39M · Avg Vol: $30K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-125.5%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Provexis plc develops and licenses the proprietary, scientifically proven heart-health ingredient Fruitflow, a natural tomato extract that helps maintain normal platelet aggregation. The company's competitive advantage is secured by strong patent protection and a positive European Food Safety Authority (EFSA) health claim, a rare distinction in the dietary supplement industry. It operates as a high-margin, IP-licensing business, partnering with global distributor DSM to commercialize Fruitflow worldwide.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0.6M	0.5M	1.1M	1.7M	44.7%	1.1M
EPS	-0.00	-0.00	-0.00	-0.00	—	—
Shares	2.2B	2.2B	2.2B	2.3B	+6.1%	2.3B
Debt	—	—	—	—	—	—
Equity	2.0M	1.6M	1.0M	1.7M	-4.7%	—
Op CF	-0.3M	-0.7M	-0.3M	-0.4M	—	-0.7M
Inv CF	103	1.2K	2.3K	2.5K	—	—
Fin CF	0	46.3K	0	1.1M	—	—

Loading 1Y...

PRICE (1Y)+35.0%

SMA 50SMA 200

$0.0178

RSI (14)

61.1

52W High

$0.0205

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-59.2%12.7

ROE

-125.5%7.2

GP/Assets

42.4%82.5

Op. Margin

-85.0%18.4

FCF/Assets

-32.1%9.7

Piotroski

439.0

Int. Cover

—N/A

D/E Ratio

0.00x97.8

Current Ratio

3.65x61.3

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

—N/A

P/S

32.2x13.1

Div Yield

—N/A

Momentum

52W High %

87%81.8

RS 6M

20%86.3

SMA 50/200

1.15x86.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$39M

P/E (Forward)

—

Gross Margin

49.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PXS.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PXS.L	Provexis plc(you)	$39M	44	HOLD
STX.L	Shield Therapeutics plc	$86M	21	SELL
EAH.L	ECO Animal Health Group plc	$78M	95	STRONG BUY
ANCR.L	Animalcare Group plc	$302M	90	STRONG BUY
AGY.L	Allergy Therapeutics plc	$630M	4	STRONG SELL
ABDX.L	Abingdon Health Plc	$34M	41	HOLD
AREC.L	Arecor Therapeutics plc	$34M	58	HOLD
HVO.L	hVIVO plc	$63M	36	HOLD
SAR.L	Sareum Holdings plc	$38M	19	STRONG SELL
SBTX.L	SkinBioTherapeutics plc	$42M	19	STRONG SELL

Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.9%

Provexis plc (PXS.L) — Stock Score Summary

Provexis plc (PXS.L) has a MoatMap StockRank of 44/100 based on Quality (40/100), Value (24/100), and Momentum (74/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$0.02
Market Cap	$39M
Return on Equity	-125.5%
Return on Invested Capital	-59.2%
Debt/Equity	0.00x
Gross Margin	49.2%
Operating Margin	-85.0%
Revenue Growth	-53.6%
Free Cash Flow	$-428K

Provexis plc operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Provexis plc’s (PXS.L) StockRank?: MoatMap’s StockRank for Provexis plc (PXS.L) is 44/100, with a Hold signal. It is a composite of Quality (40), Value (24), and Momentum (74) factor ranks across MoatMap’s 20,000+ stock universe.
Does Provexis plc have an economic moat?: Provexis plc (PXS.L) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Provexis plc a buy, hold, or sell?: MoatMap’s current signal for Provexis plc (PXS.L) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Provexis plc in?: Provexis plc (PXS.L) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United Kingdom).